Avellino Labs Adds James Mazzo to its Board of Directors

By

MENLO PARK, Calif.—Avellino Labs, a biotechnology company that develops genetic tests in ophthalmology, has added James (Jim) V. Mazzo to its board of directors. With over 38 years of experience with building and advancing major ophthalmic organizations, Mazzo is one of the industry's best-known and most respected leaders. "Jim's knowledge of the ophthalmic community underscores our mission to collaborate closely with eye care professionals to provide them with the solutions they need to best serve their patients," said Avellino Labs board chairman Gene Lee. "We believe his expertise will strengthen our efforts as we partner with clinical and scientific experts to advance the science of genetic testing and gene therapy in ophthalmology."

Mazzo is currently the global president of ophthalmic devices at Carl Zeiss Meditec. He also serves on the ASCRS governing board, the AAO Foundation advisory board, and is an executive committee member of the Medical Device Manufacturers Association. Throughout his career, Mazzo has held various executive and board leadership roles at ophthalmic organizations, including Allergan, Advanced Medical Optics, Abbott, AcuFocus, Neurotech and AdvaMed.

"Avellino Labs is the future of personal medicine in ophthalmology," said Mazzo. "I'm looking forward to working alongside these visionaries, as well as ophthalmic and optometric providers, to create new opportunities for earlier detection of diseases, leading to greater treatment options and overall better patient care."

Avellino Labs is headquartered in Silicon Valley, Calif., with operations in Korea, Japan, China and the U.K. The company was named a 2015 Technology Pioneer by the World Economic Forum based on its potential to impact global health.